ReviewAnnals of surgical oncology2026
Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn't Just Ductal.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInvasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and presents histologically with a unique pattern of discohesive growth. An expert consensus panel was convened at the annual meeting of the American Society of Breast Surgeons to discuss disease specific management considerations and best practice when caring for women with ILC.
methodsAt the annual meeting of the American Society of Breast Surgeons held in Las Vegas, Nevada from April 30 to May 4, 2025, a panel convened to specifically address the intricacies of managing ILC. Panelists completed an independent literature review for each identified subtopic that was summarized and reviewed by panel moderators.
resultsThe multidisciplinary management of ILC is nuanced and special considerations are essential to optimize treatment. Magnetic resonance imaging of the breast can improve the accuracy of preoperative staging. Surgeons should account for the limitations of imaging with respect to margin resection in lumpectomy. When considering the application of trials guiding omission of ALND in surgery for ILC, surgeons can rely on several studies that have included subanalyses of patients with ILC confirming safety in appropriately selected patients. Use of neoadjuvant therapy should be based on molecular subtype rather than tumor histology. Genetic testing for patients with ILC should include analysis of CDH1 mutations. DISCUSSION: Awareness and consideration of nuances around the management of ILC, including those discussed in the present study, can help clinicians provide optimal, evidenced based care to women presenting with ILC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.